Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8641 to 8655 of 9128 results

  1. Avacopan for treating anti-neutrophil cytoplasmic antibody-associated vasculitis [ID1178]

    Discontinued Reference number: GID-TA10199

    Technology appraisal guidance
    Discontinued

  2. Rituximab for maintenance treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis [ID1320]

    Discontinued Reference number: GID-TA10332

    Technology appraisal guidance
    Discontinued

  3. Haemochromatosis

    Discontinued Reference number: GID-NG10287

    NICE guideline
    Discontinued

  4. Type 2 diabetes in adults: management - insulin therapy

    Discontinued Reference number: GID-NG10375

    NICE guideline
    Discontinued

  5. Pegvaliase for treating phenylketonuria [ID1110]

    Discontinued Reference number: GID-TA10345

    Technology appraisal guidance
    Discontinued

  6. Pancreatic cancer (metastatic) - nimotuzumab (1st line) [ID513]

    Discontinued Reference number: GID-TAG363

    Technology appraisal guidance
    Discontinued

  7. Pancreatic cancer (metastatic, untreated) - liposomal cisplatin (with gemcitabine) [ID658]

    Discontinued Reference number: GID-TAG494

    Technology appraisal guidance
    Discontinued

  8. Sacituzumab govitecan for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment [ID6592]

    In development Reference number: GID-TA11769 Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Baloxavir marboxil for treating and preventing influenza in babies 3 weeks to under 1 year [ID6555]

    Discontinued Reference number: GID-TA11712

    Technology appraisal guidance
    Discontinued

  10. Baloxavir marboxil for preventing influenza in people 12 years and over [ID3793]

    In development Reference number: GID-TA10684 Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Trilaciclib for preventing myelosuppression caused by chemotherapy for extensive-stage small-cell lung cancer [ID6651]

    In development Reference number: GID-TA11863 Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Tolebrutinib for treating primary progressive multiple sclerosis [ID6574]

    In development Reference number: GID-TA11762 Expected publication date:  28 July 2025

    Technology appraisal guidance
    In development

  13. Ravulizumab for preventing kidney events in people with chronic kidney disease at high risk after a cardiopulmonary bypass [ID6632]

    In development Reference number: GID-TA11841 Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Sugemalimab with chemotherapy for untreated metastatic non-small-cell lung cancer [ID4001]

    In development Reference number: GID-TA10900 Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Durvalumab in combination for untreated advanced ovarian, fallopian tube or primary peritoneal cancer before and after surgery [ID6254]

    In development Reference number: GID-TA11281 Expected publication date: TBC

    Technology appraisal guidance
    In development